phenobarbital has been researched along with tamoxifen in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (28.57) | 18.2507 |
| 2000's | 8 (28.57) | 29.6817 |
| 2010's | 11 (39.29) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Sen, S; Sinha, N | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dragan, YP; Pitot, HC; Xu, YD | 1 |
| Carthew, P; De Matteis, F; Dorman, BM; Edwards, RE; Heydon, RT; Martin, EA; Smith, LL; White, IN | 1 |
| Bodell, WJ; Pathak, DN; Pongracz, K | 1 |
| Kupfer, D; Mani, C; Parkinson, A; Pearce, R | 1 |
| Bodell, WJ; Pathak, DN | 1 |
| Kupfer, D; Lee, CA; Mani, C; Rifkind, AB | 1 |
| Dehal, SS; Kupfer, D | 1 |
| Moorthy, B; Randerath, E; Randerath, K; Sriram, P | 1 |
| Davies, R; Fenwick, S; Smith, LL; Styles, JA; Walker, J; White, IN | 1 |
| Brown, JE; Brown, K; Carthew, P; Davies, R; Martin, EA; Smith, LL; Styles, J; White, IN | 1 |
| Carthew, P; Edwards, RE; Heydon, RT; Lee, PN; Martin, EA; Nolan, BM | 1 |
| Gartung, C; Geier, A; Gerloff, T; Meier, PJ; Roots, I | 1 |
| Asimiadou, S; Bittigau, P; Dzietko, M; Felderhoff-Mueser, U; Ikonomidou, C; Kaindl, AM; Manthey, D; Mozrzymas, JW; Pesditschek, S; Pytel, M; Sifringer, M; Studniarczyk, D | 1 |
| Bräuchle, C; Hermawan, A; Knyazev, P; Ljepoja, B; Mickler, FM; Roidl, A; Sommer, AK; Ullrich, A; Wagner, E | 1 |
| Bennett, L; Edwards, J; Horgan, PG; Mallon, EA; McCall, P; McMillan, DC; Paul, A; Quinn, J | 1 |
| Giannakeas, V; Narod, SA; Sopik, V | 1 |
1 review(s) available for phenobarbital and tamoxifen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
27 other study(ies) available for phenobarbital and tamoxifen
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse Reactions; Fibroblasts; Lipidoses; Lysosomal Storage Diseases; Models, Molecular; Pharmaceutical Preparations; Phospholipids; Structure-Activity Relationship; Thermodynamics | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Tumor promotion as a target for estrogen/antiestrogen effects in rat hepatocarcinogenesis.
Topics: Adenosine Triphosphatases; Administration, Oral; Animals; Biomarkers, Tumor; Carcinogens; Diethylnitrosamine; Disease Models, Animal; Drug Evaluation, Preclinical; Female; gamma-Glutamyltransferase; Glucosephosphate Dehydrogenase; Glutathione Transferase; Liver Neoplasms, Experimental; Phenobarbital; Rats; Rats, Inbred F344; Tamoxifen | 1991 |
Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital.
Topics: Animals; Biomarkers, Tumor; Carcinogens; Diet; DNA Damage; Drug Synergism; Female; Liver; Liver Neoplasms; Phenobarbital; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; Tamoxifen; Time Factors | 1995 |
Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen.
Topics: Animals; Benzene Derivatives; Biotransformation; DNA; DNA Adducts; Female; Horseradish Peroxidase; Microsomes, Liver; NADP; Phenobarbital; Rats; Rats, Sprague-Dawley; Tamoxifen | 1995 |
Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Biotransformation; Chickens; Cricetinae; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Erythromycin; Female; Humans; Hydrocortisone; Immunoglobulin G; Male; Mesocricetus; Methylcholanthrene; Metyrapone; Mice; Microsomes, Liver; Mixed Function Oxygenases; Phenobarbital; Pregnenolone Carbonitrile; Proadifen; Protein Binding; Rats; Rats, Sprague-Dawley; Species Specificity; Tamoxifen; Troleandomycin | 1994 |
DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems.
Topics: Animals; Benzene Derivatives; DNA; Female; Humans; Male; Microsomes, Liver; NADP; Phenobarbital; Rats; Tamoxifen | 1994 |
Induction of tamoxifen-4-hydroxylation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), beta-naphthoflavone (beta NF), and phenobarbital (PB) in avian liver: identification of P450 TCDDAA as catalyst of 4-hydroxylation induced by TCDD and beta NF.
Topics: Animals; Benzo(a)pyrene; Benzoflavones; beta-Naphthoflavone; Chick Embryo; Chickens; Cricetinae; Cytochrome P-450 Enzyme System; Enzyme Induction; Estrogen Antagonists; Female; Humans; Hydroxylation; Immunoglobulin G; Liver; Mesocricetus; Mice; Microsomes, Liver; Models, Biological; Phenobarbital; Polychlorinated Dibenzodioxins; Rats; Rats, Sprague-Dawley; Species Specificity; Tamoxifen | 1994 |
Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins.
Topics: Animals; Antineoplastic Agents, Hormonal; Biotransformation; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cytochrome P-450 Enzyme System; Female; Hydroxylation; Male; Microsomes, Liver; Phenobarbital; Pregnenolone Carbonitrile; Rats; Rats, Sprague-Dawley; S-Adenosylhomocysteine; S-Adenosylmethionine; Tamoxifen | 1996 |
Effects of cytochrome P450 inducers on tamoxifen genotoxicity in female mice in vivo.
Topics: Animals; Cytochrome P-450 Enzyme System; DNA Adducts; Enzyme Induction; Estrogen Antagonists; Female; Mice; Mice, Inbred ICR; Phenobarbital; Pregnenolone Carbonitrile; Tamoxifen | 1997 |
Tamoxifen mutagenesis and carcinogenesis in livers of lambda/lacI transgenic rats: selective influence of phenobarbital promotion.
Topics: Animals; Bacterial Proteins; Cell Division; Escherichia coli Proteins; Estrogen Antagonists; Female; Glutathione Transferase; Lac Repressors; Liver; Liver Neoplasms, Experimental; Mutagens; Organ Size; Phenobarbital; Rats; Rats, Inbred F344; Repressor Proteins; Tamoxifen | 2001 |
Short-term dosing of alpha-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats.
Topics: Animals; Animals, Genetically Modified; Carcinogens; Chromatography, High Pressure Liquid; Disease Progression; DNA Adducts; DNA Damage; Female; Glutathione Transferase; Hepatocytes; Liver; Liver Neoplasms; Mutation; Phenobarbital; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; Tamoxifen; Time Factors | 2001 |
Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat.
Topics: Administration, Oral; Animals; Body Weight; Carcinogens; DNA; DNA Adducts; DNA Damage; Dose-Response Relationship, Drug; Female; Liver; Liver Neoplasms, Experimental; Organ Size; Phenobarbital; Rats; Rats, Wistar; Tamoxifen; Time Factors; Uterus | 2001 |
Functional analysis of the rat bile salt export pump gene promoter.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Base Sequence; Bile Acids and Salts; Binding Sites; Dexamethasone; DNA-Binding Proteins; Feedback; Gene Expression Regulation; Genes; Genes, Reporter; Hepatoblastoma; Hepatocytes; Humans; Hydrocortisone; Liver Neoplasms; Molecular Sequence Data; Phenobarbital; Promoter Regions, Genetic; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rifampin; Tamoxifen; Transcription Factors; Transcription, Genetic; Transfection; Tumor Cells, Cultured; Xenobiotics | 2002 |
Protection with estradiol in developmental models of apoptotic neurodegeneration.
Topics: Animals; Animals, Newborn; Apoptosis; Bicuculline; Blotting, Western; Brain; Caenorhabditis elegans Proteins; Cell Count; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Antagonists; Extracellular Signal-Regulated MAP Kinases; GABA Antagonists; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Membrane Potentials; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Patch-Clamp Techniques; Phenobarbital; Phenytoin; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Receptors, GABA-A; Silver Staining; Tamoxifen | 2005 |
Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases.
Topics: Biological Transport; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Endosomes; Estrogen Receptor alpha; Female; Humans; Inhibitory Concentration 50; Ligands; Lysosomes; MCF-7 Cells; Phenobarbital; Pyrans; Receptor Protein-Tyrosine Kinases; Selective Estrogen Receptor Modulators; Tamoxifen | 2016 |
High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.
Topics: Aged; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cytoplasm; Disease-Free Survival; Estrogen Receptor alpha; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; I-kappa B Kinase; Immunohistochemistry; Ligands; MCF-7 Cells; Middle Aged; Neoplasm Recurrence, Local; Phenobarbital; Prognosis; Retrospective Studies; RNA, Small Interfering; Tamoxifen; Treatment Outcome | 2017 |
Late Recurrences After Estrogen Receptor-Positive Breast Cancer.
Topics: Breast Neoplasms; Humans; Phenobarbital; Postmenopause; Receptors, Estrogen; Recurrence; Tamoxifen | 2020 |